With sales sagging, Amarin sees progress on new Vascepa digital effort in the US

March 2020 was a challenging month for everyone as the pandemic spread worldwide. But it was especially so for Amarin as its key patents for its lone product, fish oil derivative Vascepa, were invalidated.

The timing couldn’t have been worse. Just three months earlier, Amarin had earned a game-changing FDA approval for Vascepa, transforming it from merely a way to reduce cholesterol to a means of lowering the risk of cardiovascular disease.